Synapse - Works

Results (216)

PRESTO: A phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)

Journal Article

Aggarwal, R.; Heller, G.; Hillman, D. W.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T.; Appleman, L.; Weckstein, D.; Patnaik, A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Radiographic progression-free survival and clinical progression-free survival as potential surrogates for overall survival in men with metastatic hormone-sensitive prostate cancer

Journal Article

Halabi, S.; Roy, A.; Rydzewska, L.; Guo, S.; Godolphin, P.; Hussain, M.; Tangen, C.; Thompson, I.; Xie, W.; Carducci, M. A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

PSMAddition: A phase 3 trial to compare treatment with (177)Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer

Meeting Abstract

Tagawa, S. T.; Sartor, A. O.; Saad, F.; Reid, A. H.; Sakharova, O. V.; Feng, F. Y.; Fizazi, K.; Morris, M. J.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001)

Meeting Abstract

Gupta, S.; Ballman, K. V.; Galsky, M. D.; Morris, M. J.; Sridhar, S. S.; Chen, R. C.; Chan, T. A.; Wen, Y.; Grivas, P.; Tan, A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19)

Meeting Abstract

Aggarwal, R. R.; Dooley, K.; Hillman, D. W.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T. B.; Appleman, L. J.; Weckstein, D. J.; Patnaik, A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC)

Meeting Abstract

Halabi, S.; Guo, S. S.; Roy, A.; Rydzewska, L.; Godolphin, P.; Hussain, M. H. A.; Tangen, C.; Thompson, I.; Xie, W.; Carducci, M. A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Tumor dosimetry of [(177)Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study

Meeting Abstract

Krause, B. J.; Chi, K. N.; Sartor, A. O.; Fizazi, K.; Morris, M. J.; De Bono, J. S.; Tagawa, S. T.; Herrmann, K.; Kurth, J.; Eiber, M.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

Meeting Abstract

Halabi, S.; Roy, A.; Guo, S. S.; Rydzewska, L.; Godolphin, P.; Hussain, M. H. A.; Tangen, C.; Thompson, I.; Xie, W.; Carducci, M. A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies

Meeting Abstract

Jensen, J. L.; Bobek, O.; Chan, I. C. C.; Hillman, D. W.; Heller, G.; Druley, T. E.; Morris, M. J.; Milowsky, M. I.; Beltran, H.; Bolton, K. L.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Building a predictive model for outcomes with [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results

Meeting Abstract

Herrmann, K.; Gafita, A.; De Bono, J. S.; Sartor, A. O.; Chi, K. N.; Krause, B. J.; Rahbar, K.; Tagawa, S. T.; Czernin, J.; El-Haddad, G.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save